Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence
C Gridelli, F De Marinis, M Di Maio, D Cortinovis… - Lung Cancer, 2011 - Elsevier
Gefitinib is a small molecule tyrosine kinase inhibitor of epidermal growth factor receptor
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …
The evolution of therapies in non-small cell lung cancer
V Boolell, M Alamgeer, DN Watkins, V Ganju - Cancers, 2015 - mdpi.com
The landscape of advanced non-small lung cancer (NSCLC) therapies has rapidly been
evolving beyond chemotherapy over the last few years. The discovery of oncogenic driver …
evolving beyond chemotherapy over the last few years. The discovery of oncogenic driver …
Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): a mutual association with airway disease
NSCLC is a leading cause of morbidity and mortality worldwide. It includes adeno-and
squamous cell carcinoma. In the background, COPD and smoking play a vital role in …
squamous cell carcinoma. In the background, COPD and smoking play a vital role in …
EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
M He, M Capelletti, K Nafa, CH Yun, ME Arcila… - Clinical cancer …, 2012 - AACR
Purpose: Epidermal growth factor receptor (EGFR) genotyping is now standard in the
management of advanced lung adenocarcinoma, as this biomarker predicts marked benefit …
management of advanced lung adenocarcinoma, as this biomarker predicts marked benefit …
Treating patients with EGFR-sensitizing mutations: first line or second line—is there a difference?
T Mok, JJ Yang, KC Lam - Journal of clinical oncology, 2013 - ascopubs.org
First-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) is a standard
treatment for patients with activating EGFR mutations. Six randomized studies have …
treatment for patients with activating EGFR mutations. Six randomized studies have …
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study …
G Yamamoto, H Asahina, O Honjo, T Sumi… - Scientific reports, 2021 - nature.com
Osimertinib is a standard of care therapy for previously untreated epidermal growth factor
receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding …
receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding …
Different treatment efficacies and T790M acquisition of EGFR‐TKIs on NSCLC patients with variable Del‐19 subtypes of EGFR
SG Wu, CH Gow, YL Chen, YN Liu… - … Journal of Cancer, 2023 - Wiley Online Library
Abstract EGFR exon 19 deletion (Del‐19) comprises multiple advanced NSCLC subtypes.
EGFR‐tyrosine kinase inhibitor (TKI) efficacy and T790M acquisition in various Del‐19 …
EGFR‐tyrosine kinase inhibitor (TKI) efficacy and T790M acquisition in various Del‐19 …
Expression of the epithelial-mesenchymal transition-related proteins and their clinical significance in lung adenocarcinoma
Y Shi, H Wu, M Zhang, L Ding, F Meng, X Fan - Diagnostic pathology, 2013 - Springer
Background Epithelial-mesenchymal transition (EMT) is defined as switching of polarized
epithelial cells to a migratory fibroblastoid phenotype. EMT is known to be involved in the …
epithelial cells to a migratory fibroblastoid phenotype. EMT is known to be involved in the …
A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations
H Imai, K Kaira, K Suzuki, M Anzai, T Tsuda, T Ishizuka… - Lung Cancer, 2018 - Elsevier
Objective The efficacy and safety of afatinib in elderly patients with EGFR-mutated non-small-
cell lung cancer (NSCLC) have not been evaluated. This study aimed to assess the efficacy …
cell lung cancer (NSCLC) have not been evaluated. This study aimed to assess the efficacy …
Epidermal growth factor receptor tyrosine kinase inhibitor-sensitive exon 19 insertion and exon 20 insertion in patients with advanced non–small-cell lung cancer
YT Lin, YN Liu, SG Wu, JCH Yang, JY Shih - Clinical Lung Cancer, 2017 - Elsevier
Background The clinical responsiveness to epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors (TKIs) in non–small-cell lung cancer (NSCLC) patients with exon …
tyrosine kinase inhibitors (TKIs) in non–small-cell lung cancer (NSCLC) patients with exon …